Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Stromal Androgen Receptor in Prostate Cancer Development and Progression.

Leach DA, Buchanan G.

Cancers (Basel). 2017 Jan 22;9(1). pii: E10. doi: 10.3390/cancers9010010. Review.

2.

Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.

Kumon H, Ariyoshi Y, Sasaki K, Sadahira T, Araki M, Ebara S, Yanai H, Watanabe M, Nasu Y.

Cancer Gene Ther. 2016 Nov;23(11):400-409. doi: 10.1038/cgt.2016.53.

3.

Feasibility of Neoadjuvant Ad-REIC Gene Therapy in Patients with High-Risk Localized Prostate Cancer Undergoing Radical Prostatectomy.

Kumon H, Sasaki K, Ariyoshi Y, Sadahira T, Araki M, Ebara S, Yanai H, Watanabe M, Nasu Y.

Clin Transl Sci. 2015 Dec;8(6):837-40. doi: 10.1111/cts.12362.

4.

Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.

Hu J, Xu H, Zhu W, Wu F, Wang J, Ding Q, Jiang H.

World J Surg Oncol. 2015 Feb 22;13:73. doi: 10.1186/s12957-015-0503-z. Review.

5.

Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.

Taira AV, Merrick GS, Galbreath RW, Morris M, Butler WM, Adamovich E.

J Contemp Brachytherapy. 2014 Oct;6(3):254-61. doi: 10.5114/jcb.2014.45757.

6.

Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.

Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK, Lam KS, Tse HF, Yau T, Siu CW.

J Oncol. 2014;2014:529468. doi: 10.1155/2014/529468.

7.

Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.

Lou DY, Fong L.

Urol Oncol. 2016 Apr;34(4):182-92. doi: 10.1016/j.urolonc.2013.12.001. Review.

PMID:
24495446
8.

Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.

McKay RR, Choueiri TK, Taplin ME.

Drugs. 2013 Sep;73(13):1417-30. doi: 10.1007/s40265-013-0107-2. Review.

9.

An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Perlroth DJ, Bhattacharya J, Goldman DP, Garber AM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):250-7. doi: 10.1093/jncimonographs/lgs037.

10.

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.

Choi S, Lee AK.

Drug Healthc Patient Saf. 2011;3:107-19. doi: 10.2147/DHPS.S24106.

11.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Review.

12.

Contemporary radical prostatectomy.

Fu Q, Moul JW, Sun L.

Prostate Cancer. 2011;2011:645030. doi: 10.1155/2011/645030.

13.

First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients.

Røder MA, Berg KD, Gruschy L, Brasso K, Iversen P.

Prostate Cancer. 2011;2011:236357. doi: 10.1155/2011/236357.

14.

Hormone therapy in the management of prostate cancer: evidence-based approaches.

Gomella LG, Singh J, Lallas C, Trabulsi EJ.

Ther Adv Urol. 2010 Aug;2(4):171-81. doi: 10.1177/1756287210375270.

15.

Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

O'Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM.

Am J Clin Pathol. 2010 Apr;133(4):654-61. doi: 10.1309/AJCP8EL5FTZSOBIH.

16.

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.

Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960.

17.

Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.

Yee DS, Lowrance WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F.

BJU Int. 2010 Jan;105(2):185-90. doi: 10.1111/j.1464-410X.2009.08698.x.

18.

Prostate cancer (early).

James ML.

BMJ Clin Evid. 2006 Oct 1;2006. pii: 1805. Review.

19.

Role of androgen deprivation therapy for node-positive prostate cancer.

Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K.

J Clin Oncol. 2009 Jan 1;27(1):100-5. doi: 10.1200/JCO.2007.14.2042.

20.

Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA.

J Clin Oncol. 2007 Nov 1;25(31):4998-5008. Review.

Supplemental Content

Support Center